A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting
- DOI
- 10.1093/oncolo/oyag279
- Published
- 2026-07-22
- Container
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1093/oncolo/oyag279,
title = {A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting},
author = {Suzanne Jones and Gerald Falchook and Stephanie Graff and Edward Arrowsmith and Deepak Kilari and Todd A Gersten and Maen Hussein and Ivor Percent and Howard A Burris},
year = {2026},
journal = {The Oncologist},
doi = {10.1093/oncolo/oyag279},
url = {https://doi.org/10.1093/oncolo/oyag279}
}RIS
TY - JOUR TI - A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting AU - Suzanne Jones AU - Gerald Falchook AU - Stephanie Graff AU - Edward Arrowsmith AU - Deepak Kilari AU - Todd A Gersten AU - Maen Hussein AU - Ivor Percent AU - Howard A Burris PY - 2026 JO - The Oncologist DO - 10.1093/oncolo/oyag279 UR - https://doi.org/10.1093/oncolo/oyag279 ER -
APA
Jones, S., Falchook, G., Graff, S., Arrowsmith, E., Kilari, D., Gersten, T. A., Hussein, M., Percent, I., & Burris, H. A. (2026). A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting. The Oncologist. https://doi.org/10.1093/oncolo/oyag279
Source records
- crossref · retrieved 2026-09-25T03:45:52.470Z